Synta has a diverse pipeline of novel, small molecule drug candidates targeting
cancer and inflammatory diseases, two of the largest therapeutic markets in the
world.
Each program represents an independent drug category with a distinct chemical
family and mechanism of action. All of our clinical candidates were developed
internally and Synta currently fully owns all rights in all geographic markets
and in all indications.
|
